N-[2-[(dimethylamino)methyl]-1,3-benzothiazol-5-yl]-6-(4-fluorophenyl)-2-methylpyridine-3-carboxamide | 1089671-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[2-[(dimethylamino)methyl]-1,3-benzothiazol-5-yl]-6-(4-fluorophenyl)-2-methylpyridine-3-carboxamide
• CAS: 1089671-56-6
• 化学式: C₂₃H₂₁FN₄OS
• 分子量: 420.51
• InChiKey: PFLDLYJDEAJBMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-[(dimethylamino)methyl]-1,3-benzothiazol-5-amine 、 6-(4-fluorophenyl)-2-methyl-3-pyridinecarboxylic acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-[2-[(dimethylamino)methyl]-1,3-benzothiazol-5-yl]-6-(4-fluorophenyl)-2-methylpyridine-3-carboxamide
  参考文献：
  名称：

  Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1

  摘要：

  6-Phenylnicotinamide (2) was previously identified as a potent TRPV1 antagonist with activity in an in vivo model of inflammatory pain. Optimization of this lead through modi. cation of both the biaryl and heteroaryl components has resulted in the discovery of 6-(4-fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl) nicotinamide (32; SB-782443) which possesses an excellent overall pro. le and has been progressed into pre-clinical development. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.105

文献信息

• Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1
  作者：Susan M. Westaway、Mervyn Thompson、Harshad K. Rami、Geoffrey Stemp、Leontine S. Trouw、Darren J. Mitchell、Jon T. Seal、Stephen J. Medhurst、Sarah C. Lappin、James Biggs、James Wright、Sandra Arpino、Jeffrey C. Jerman、Jennifer E. Cryan、Vicky Holland、Kim Y. Winborn、Tanya Coleman、Alexander J. Stevens、John B. Davis、Martin J. Gunthorpe

  DOI：10.1016/j.bmcl.2008.08.105

  日期：2008.10

  6-Phenylnicotinamide (2) was previously identified as a potent TRPV1 antagonist with activity in an in vivo model of inflammatory pain. Optimization of this lead through modi. cation of both the biaryl and heteroaryl components has resulted in the discovery of 6-(4-fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl) nicotinamide (32; SB-782443) which possesses an excellent overall pro. le and has been progressed into pre-clinical development. (C) 2008 Elsevier Ltd. All rights reserved.